Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rembrandt: Pardoprunox Monotherapy in Early Parkinson's Disease
NCT00269516Phase 3Completed
- Sponsor
- Solvay
- Start
- Jun 2006
- Primary completion
- Dec 2007
- Modality
- Small Molecules
- Countries
- 21
01
Overview
Phase 3, randomised, double-blind trial of pardoprunox in Parkinson's disease (PD) (4 arms), sponsored by Solvay. Primary endpoint: Unified Parkinson's Disease Rating Scale Part III (Motor Score) at 24 weeks. Started Jun 2006; status: completed.
02
Drugs
pardoprunox
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT00269516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00269516.